Novartis slots PhI cardiovascular candidate into pipeline, paying Korean partner $80M upfront
Phase 1License out/inAHA
Novartis is plucking a Phase I small molecule candidate out of Korea that it believes can treat a variety of diseases — including certain cardiovascular conditions.
Handing Chong Kun Dang Pharmaceutical (CKD) an upfront payment of $80 million, Novartis bought exclusive rights to an HDAC6 inhibitorHDAC6 inhibitor, dubbed CKD-510, everywhere in the world except in Korea. Milestones can add up to $1.225 billion before counting tiered royalties, making it CKDCKD’s largest contract ever, CEO Kim Young-Joo told Korea BioMed.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.